(Q39296351)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28490260%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

review article

1 reference

title

Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28490260%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28490260%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Clive Ballard

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28490260%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Ayesha Khan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28490260%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

18 May 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28490260%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

20 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28490260%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28490260%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28490260%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

683-695

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28490260%20AND%20SRC:MED&resulttype=core&format=json

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

20 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Resolving controversies on the path to Alzheimer's therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Secretase inhibitors and modulators for Alzheimer's disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Recommendations for best practices in the treatment of Alzheimer's disease in managed care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Antipsychotic drug use among nursing home residents taking rivastigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Effects of risperidone, clozapine and the 5-HT6 antagonist GSK-742457 on PCP-induced deficits in reversal learning in the two-lever operant task in male Sprague Dawley rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

5-HT(6) receptor and cognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

M1 agonists as a potential disease-modifying therapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

M1 receptors play a central role in modulating AD-like pathology in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

The M1 Muscarinic Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of Memory and Attention in Rhesus Monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Progresses in treating agitation: a major clinical challenge in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

AMPA potentiator treatment of cognitive deficits in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

A molecular link between the active component of marijuana and Alzheimer's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Drug repositioning for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

(Val⁸) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Brain renin-angiotensin--a new look at an old system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Anti-amyloidogenic activity of tetracyclines: studies in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Fyn inhibition rescues established memory and synapse loss in Alzheimer mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

The evolution of preclinical Alzheimer's disease: implications for prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Modulating nitric oxide signaling in the CNS for Alzheimer's disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Retinoic acid normalizes nuclear receptor mediated hypo-expression of proteins involved in beta-amyloid deposits in the cerebral cortex of vitamin A deprived rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Macrophage colony-stimulating factor augments beta-amyloid-induced interleukin-1, interleukin-6, and nitric oxide production by microglial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APPswe/PSEN1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Hippocampal hypometabolism predicts cognitive decline from normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Intranasal insulin improves cognition and modulates beta-amyloid in early AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Cognitive training for early-stage Alzheimer's disease and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: Randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Putting brain training to the test

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Exercise training increases size of hippocampus and improves memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Effects of aerobic exercise on mild cognitive impairment: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Early-stage and preclinical Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2017.1326818

10.1080/14737175.2017.1326818

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28490260%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference